Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib for inoperable or relapsing PVNS/TGCT
ACTRN12612000019808Phase 2Not yet recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in tenosynovial giant cell tumor (TGCT), sponsored by Centre Léon Bérard. Primary endpoint: Non-progression rate at 12 weeks by central review. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
nilotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on ACTRN12612000019808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000019808.